

 Phone:
 888-558-5227

 651-644-8424

 Fax:
 888-558-7329

 Email:
 getinfo@lktlabs.com


 Web:
 lktlabs.com

Product Information

Product ID A985134 CAS No. 1421373-65-0 Chemical Name

Synonym AZD 9291, AZD9291, Osimertinib, Mereletinib

Formula C₂₈H₃₃N₇O₂ Formula Wt. 499.62 Melting Point Purity ≥98% Solubility



Bulk quanitites available upon request

Product ID	Size
A985134	25 mg
A985134	100 mg
A985134	250 mg

Store Temp -20°C

Ship Temp Ambient

Description AZD-9291 is an irreversible inhibitor of EGFR. It is approved for the treatment of metastatic EGFR T790M mutation-positive nonsmall cell lung cancer (NSCLC) in patients failing previous tyrosine kinase therapy, and more recently also in T790M negative NSCLC patients. Combination therapy with pemetrexed and cisplatin is currently being studied to delay or overcome resistance to AZD-9291 that is commonly experienced by patients after prolonged treatment.

References Bollinger M., Agnew A., et al. Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation. J Oncol Pharm PRact. 24(5):279-388 (2018). PMID: 28565936.

La Monica S., Minari R., Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC. J Exp Clin Cancer Res. 38(1):222 (2019). PMID: 31138260.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.